Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

Publication Type
Journal Article
Year of Publication
Goji, Nega Ali; Nolan, Carrie; Hill, Heather; Wolff, Mark; Noah, Diana L; Williams, Tracy B; Rowe, Thomas; Treanor, John J
J Infect Dis
Date Published
2008 Sep 01
Adolescent; Adult; Antibodies, Viral; Antigens, Viral; Dose-Response Relationship, Immunologic; Female; Humans; Immunization Schedule; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Vaccines, Inactivated

BACKGROUND: We administered a single dose of influenza A/Vietnam/1203/2004 (H5N1, clade 1) vaccine to subjects who had received 2 doses of influenza A/Hong Kong/156/1997 (H5N1, clade 0) vaccine in 1998.

METHODS: Thirty-seven subjects previously vaccinated with a baculovirus-expressed recombinant hemagglutinin A/Hong Kong/156/1997 vaccine in 1998 received a single intramuscular dose of 90 microg of inactivated subvirion A/Vietnam/1203/2004 vaccine in 2006. Serum antibody was measured before vaccination and 28 and 56 days after vaccination. Antibody responses were compared with those measured after one or two 90-microg doses in H5-naive subjects.

RESULTS: On day 28 after a single dose, the geometric mean titer (GMT) of hemagglutination-inhibition antibody in primed subjects was 64.0 (95% confidence interval [CI], 37.8-108.5), with 68% responding (4-fold increase in antibody level to a titer of >or=1:40). In contrast, H5-naive subjects who received two 90-microg doses had a day 56 (28 days after the second dose) GMT of 27.7 (95% CI, 20.3-38.0), with only 43% responding.

CONCLUSIONS: This study suggests that priming can result in immune responses to a single dose of an antigenically variant strain of H5N1 influenza virus and could be a useful strategy for pandemic control.

TRIAL REGISTRATION: identifier: NCT00240903.